-
1Academic Journal
Συγγραφείς: Olga A. Klochkova, Ekaterina P. Kolesnikova, Dmitriy Yu. Zinenko, Evgeniya M. Berdichevskaya, О. А. Клочкова, Е. П. Колесникова, Д. Ю. Зиненко, Е. М. Бердичевская
Συνεισφορές: Not specified, Не указан
Πηγή: Current Pediatrics; Том 21, № 1 (2022); 19-28 ; Вопросы современной педиатрии; Том 21, № 1 (2022); 19-28 ; 1682-5535 ; 1682-5527
Θεματικοί όροι: спастический тетрапарез, cerebral palsy, spasticity, spastic diplegia, spastic quadriplegia, детский церебральный паралич, спастичность, спастическая диплегия
Περιγραφή αρχείου: application/pdf
Relation: https://vsp.spr-journal.ru/jour/article/view/2841/1145; Bax M. Goldstein M, Rosenbaum P, et al. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005;47(8):571–576. doi: https://doi.org/10.1017/s001216220500112x; Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8–14.; Бадалян Л.О., Журба Л.Т., Тимонина О.В. Детские церебральные параличи. — Киев: Здоровьe, 1988. — 328 с.; Клочкова О.А., Куренков А.Л. Ботулинотерапия при детском церебральном параличе: практические советы и ультразвуковой контроль. — М.: МЕДпресс-информ, 2020. — 248 с.; Куренков А.Л., Батышева Т.Т., Виноградов А.В. и др. Спастичность при детском церебральном параличе: диагностика и стратегии лечения // Журнал неврологии и психиатрии им. C.C. Корсакова. — 2012. — Т. 112. — № 7–2. — С. 24–28.; Graham HK. Botulinum toxin A in cerebral palsy: Functional outcomes. J Pediatr. 2000;137(3):300–303. doi: https://doi.org/10.1067/mpd.2000.109107; Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP (eds). Spasticity: Disordered Motor Control; 1980. P. 485–494.; Ganguly J, Kulshreshtha D, Almotiri M, et al. Muscle Tone Physiology and Abnormalities. Toxins (Basel). 2021;13(4):282. doi: https://doi.org/10.3390/toxins13040282; Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep. 2020;20(2):3. doi: https://doi.org/10.1007/s11910-020-1022-z; Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010;14(1): 45–66. doi: https://doi.org/10.1016/j.ejpn.2009.09.005; Graham D, Aquilina K, Mankad K, et al. Selective dorsal rhizotomy: Current state of practice and the role of imaging. Quant Imaging Med Surg. 2018;8(2):209–218. doi: https://doi.org/10.21037/qims.2018.01.08; Умнов В.В. Нейрохирургические аспекты комплексного ортопедо-нейрохирургического лечения спастических параличей у детей // Вестник Российской Военно-медицинской академии. — 2008. — Т. 21. — № 1. — С. 87–91.; Королев А.А. Возможные методы нейрохирургической коррекции мышечной спастичности // Современные наукоемкие технологии. — 2012. — № 8. — С. 26–27.; Комфорт А.В., Семенова Ж.Б., Понина И.В. Селективная дорсальная ризотомия в коррекции спастического синдрома у больных детским церебральным параличом // Российский вестник детской хирургии, анестезиологии и реаниматологии. — 2014. — Т. 4. — № 4. — С. 130–135.; Кенис В.М., Иванов С.В., Киселева Т.И. Возможности селективной дорзальной ризотомии при деформациях стоп у детей с ДЦП // Ортопедия, травматология и восстановительная хирургия детского возраста. — 2015. — Т. 3. — № 1. — C. 22–26. doi: https://doi.org/10.17816/PTORS3122-26; Хаджиев О.Ч., Сиротюк М.В. Неоднозначность результатов селективной дорзальной ризотомии при детском церебральном параличе и электромиографическая объективность // Вестник физиотерапии и курортологии. — 2015. — Т. 23. — № 3. — С. 16–22.; Акижанова И.В., Кожанова А.М., Кариева Э. и др. Анализ эффективности селективной дорзальной ризотомии в сочетании с послеоперационной реабилитацией у пациентов со спастической формой ЦП с позиций МКФ (пилотный проект) // Вестник Казахского национального медицинского университета. — 2021. — № 1. — С. 115–122. doi: https://doi.org/10.53065/kaznmu.2021.60.54.027; Park TS, Dobbs MB, Cho J. Evidence Supporting Selective Dorsal Rhizotomy for Treatment of Spastic Cerebral Palsy. Cureus. 2018;10(10):e3466. doi: https://doi.org/10.7759/cureus.3466; Nicolini-Panisson RD, Tedesco AP, Folle MR, et al. Selective dorsal rhizotomy in cerebral palsy: selection criteria and postoperative physical protocols. Rev Paul Pediatr. 2018;36(1):9. doi: https://doi.org/10.1590/1984-0462/;2018;36;1;00005; Grunt S, Fieggen AG, Vermeulen RJ, et al. Selection criteria for selective dorsal rhizotomy in children with spastic cerebral palsy: A systematic review of the literature. Dev Med Child Neurol. 2014;56(4):302–312. doi: https://doi.org/10.1111/dmcn.12277; Foerster O. Über eine neue operative Methode der Behandlung spastischer Lähmungen mittels Resektion hinterer Rückenmarkswurzeln. Z Orthop Chir. 1908;22:203–223.; Gros C, Ouaknine G, Vlahovitch B, et al. La radicotomie sélective postérieure dans le traitement neuro-chirurgical de l’hypertonie pyramidale [Selective posterior radicotomy in the neurosurgical treatment of pyramidal hypertension]. Neurochirurgie. 1967;13(4):505–518.; Fasano VA, Broggi G, Barolat-Romana G, et al. Surgical treatment of spasticity in cerebral palsy. Childs Brain. 1978;4(5):289–305. doi: https://doi.org/10.1159/000119785; Peacock WJ, Arens LJ. Selective posterior rhizotomy for the relief of spasticity in cerebral palsy. S Afr Med J. 1982;62(4):119–124.; Hesselgard K, Reinstrup P, Stromblad LG, et al. Selective dorsal rhizotomy and postoperative pain management. A worldwide survey. Pediatr Neurosurg. 2007;43:107–112. doi: https://doi.org/10.1159/000098382; Park TS, Johnston JM. Surgical techniques of selective dorsal rhizotomy for spastic cerebral palsy. Technical note. Neurosurg Focus. 2006;21(2):e7.; Park TS, Liu JL, Edwards C, et al. Functional Outcomes of Childhood Selective Dorsal Rhizotomy 20 to 28 Years Later. Cureus. 2017;9(5):e1256. doi: https://doi.org/10.7759/cureus.1256; Wang KK, Munger ME, Chen BP, et al. Selective dorsal rhizotomy in ambulant children with cerebral palsy. J Child Orthop. 2018;12(5): 413–427. doi: https://doi.org/10.1302/1863-2548.12.180123; Peacock WJ, Staudt LA. Functional outcomes following selective posterior rhizotomy in children with cerebral palsy. J Neurosurg. 1991;74(3):380–385. doi: https://doi.org/10.3171/jns.1991.74.3.0380; Park TS, Joh S, Walter DM, et al. Selective Dorsal Rhizotomy for the Treatment of Spastic Hemiplegic Cerebral Palsy. Cureus. 2020;12(8):e9605. doi: https://doi.org/10.7759/cureus.9605; Park TS, Joh S, Walter DM, et al. Selective Dorsal Rhizotomy for Treatment of Hereditary Spastic Paraplegia-Associated Spasticity in 37 Patients. Cureus. 2021;13(9):e17690. doi: https://doi.org/10.7759/cureus.17690; Peacock WJ, Arens LJ, Berman B. Cerebral palsy spasticity: Selective posterior rhizotomy. Pediatr Neurosci. 1987;13(2):61–66. doi: https://doi.org/10.1159/000120302; Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2): 206–207. doi: https://doi.org/10.1093/ptj/67.2.206; Morris SL, Williams G. A historical review of the evolution of the Tardieu Scale. Brain Inj. 2018;32(5):665–669. doi: https://doi.org/10.1080/02699052.2018.1432890; Medical Research Council. Aids to the examination of the peripheral nervous system, Memorandum No. 45, 1976. Available from: https://www.ukri.org/councils/mrc/facilities-and-resources/find-an-mrc-facility-or-resource/mrc-muscle-scale/; Schwartz MH, Rozumalski A, Steele KM. Dynamic motor control is associated with treatment outcomes for children with cerebral palsy. Dev Med Child Neurol. 2016;58(11):1139–1145. doi: https://doi.org/10.1111/dmcn.13126; Roberts A, Stewart C, Freeman R. Gait analysis to guide a selective dorsal rhizotomy program. Gait Posture. 2015;42(1): 16–22. doi: https://doi.org/10.1016/j.gaitpost.2015.04.004; van de Pol LA, Vermeulen RJ, van’t Westende C, et al. Risk Factors for Dystonia after Selective Dorsal Rhizotomy in Nonwal king Children and Adolescents with Bilateral Spasticity. Neuropediatrics. 2018;49(1):44–50. doi: https://doi.org/10.1055/s-0037-1607395; Jethwa A, Mink J, Macarthur C, et al. Development of the Hypertonia Assessment Tool (HAT): A discriminative tool for hypertonia in children. Dev Med Child Neurol. 2010;52(5):e83–e87. doi: https://doi.org/10.1111/j.1469-8749.2009.03483.x; Bax M, Tydeman C, Flodmark O. Clinical and MRI correlates of cerebral palsy: the European Cerebral Palsy Study. JAMA. 2006;296(13):1602–1608. doi: https://doi.org/10.1001/jama.296.13.1602; Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol. 2009;8(1):110–124. doi: https://doi.org/10.1016/S1474-4422(08)70294-1; Tedroff K, Hägglund G, Miller F. Long-term effects of selective dorsal rhizotomy in children with cerebral palsy: a systematic review. Dev Med Child Neurol. 2020;62(5):554–562. doi: https://doi.org/10.1111/dmcn.14320; Ailon T, Beauchamp R, Miller S, et al. Long-term outcome after selective dorsal rhizotomy in children with spastic cerebral palsy. Childs Nerv Syst. 2015;31(3):415–423. doi: https://doi.org/10.1007/s00381-015-2614-9; Bolster EA, van Schie PE, Becher JG, et al. Long-term effect of selective dorsal rhizotomy on gross motor function in ambulant children with spastic bilateral cerebral palsy, compared with reference centiles. Dev Med Child Neurol. 2013;55(7):610–616. doi: https://doi.org/10.1111/dmcn.12148; Dudley RW, Parolin M, Gagnon B, et al. Long-term functional benefits of selective dorsal rhizotomy for spastic cerebral palsy. J Neurosurg Pediatr. 2013;12(2):142–150. doi: https://doi.org/10.3171/2013.4.PEDS12539; Josenby AL, Wagner P, Jarnlo GB, et al. Motor function after selective dorsal rhizotomy: A 10-year practice-based followup study. Dev Med Child Neurol. 2012;54(5):429–435. doi: https://doi.org/10.1111/j.1469-8749.2012.04258.x; Tedroff K, Lowing K, Jacobson DN, et al. Does loss of spasticity matter? A 10-year follow-up after selective dorsal rhizotomy in cerebral palsy. Dev Med Child Neurol. 2011;53(8):724–729. doi: https://doi.org/10.1111/j.1469-8749.2011.03969.x; Tedroff K, Löwing K, Åström E. A prospective cohort study investigating gross motor function, pain, and health-related quality of life 17 years after selective dorsal rhizotomy in cerebral palsy. Dev Med Child Neurol. 2015;57(5):484–490. doi: https://doi.org/10.1111/dmcn.12665; Klochkova OA, Kurenkov AL. Muscular Weakness and Loss of Motor Skills in Patients with Cerebral Palsy. Current Pediatrics. 2020;19(2):107–115. (In Russ.)] doi: https://doi.org/10.15690/vsp.v19i2.2103; Linden O, Hagglund G, Rodby-Bousquet E, et al. The development of spasticity with age in 4,162 children with cerebral palsy: A register-based prospective cohort study. Acta Orthop. 2019;90(3):286–291. doi: https://doi.org/10.1080/17453674.2019.1590769; Steinbok P, Reiner AM, Beauchamp R, et al. A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy. Dev Med Child Neurol. 1997;39(3):178–184. doi: https://doi.org/10.1111/j.1469-8749.1997.tb07407.x; Wright FV, Sheil EM, Drake JM, et al. Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: a randomized controlled trial. Dev Med Child Neurol. 1998;40(4): 239–247. doi: https://doi.org/10.1111/j.1469-8749.1998.tb15456.x; MacWilliams BA, Johnson BA, Shuckra AL, et al. Functional decline in children undergoing selective dorsal rhizotomy after age 10. Dev Med Child Neurol. 2011;53(8):717–723. doi: https://doi.org/10.1111/j.1469-8749.2011.04010.x; Steinbok P, McLeod K. Comparison of motor outcomes after selective dorsal rhizotomy with and without preoperative intensified physiotherapy in children with spastic diplegic cerebral palsy. Pediatr Neurosurg. 2002;36(3):142–147. doi: https://doi.org/10.1159/000048369; Клочкова О.А., Куренков А.Л., Кенис В.М. Формирование контрактур при спастических формах детского церебрального паралича: вопросы патогенеза // Ортопедия, травматология и восстановительная хирургия детского возраста. — 2018. — Т. 6. — № 1. — С. 58–66. doi: https://doi.org/10.17816/PTORS6158-66; Munger ME, Aldahondo N, Krach LE, et al. Long-term outcomesafter selective dorsal rhizotomy: a retrospective matched cohort study. Dev Med Child Neurol. 2017;59(11):1196–1203. doi: https://doi.org/10.1111/dmcn.13500; Chicoine MR, Park TS, Kaufman BA. Selective dorsal rhizotomy and rates of orthopedic surgery in children with spastic cerebral palsy. J Neurosurg. 1997;86(1):34–39. doi: https://doi.org/10.3171/jns.1997.86.1.0034; O’Brien DF, Park TS, Puglisi JA, et al. Orthopedic surgery after selective dorsal rhizotomy for spastic diplegia in relation to ambulatory status and age. J Neurosurg. 2005;103(1Suppl):5–9. doi: https://doi.org/10.3171/ped.2005.103.1.0005; Hicdonmez T, Steinbok P, Beauchamp R, et al. Hip joint subluxation after selective dorsal rhizotomy for spastic cerebral palsy. J Neurosurg. 2005;103(1Suppl):10–16. doi: https://doi.org/10.3171/ped.2005.103.1.0010; Nordmark E, Josenby AL, Lagergren J, et al. Long-term outcomes five years after selective dorsal rhizotomy. BMC Pediatr. 2008;8:54. doi: https://doi.org/10.1186/1471-2431-8-54; Miller SD, Juricic M, Hesketh K, et al. Prevention of hip displacement in children with cerebral palsy: a systematic review. Dev Med Child Neurol. 2017;59(11):1130–1138. doi: https://doi.org/10.1111/dmcn.13480; Limpaphayom N, Stewart S, Wang L, et al. Functional outcomes after selective dorsal rhizotomy followed by minimally invasive tendon lengthening procedures in children with spastic cerebral palsy. J Pediatr Orthop B. 2020;29(1):1–8. doi: https://doi.org/10.1097/BPB.0000000000000642; Langerak NG, Vaughan CL, Hoffman EB, et al. Incidence of spinal abnormalities in patients with spastic diplegia 17 to 26 years after selective dorsal rhizotomy. Child Nerv Syst. 2009;25(12): 1593–1603. doi: https://doi.org/10.1007/s00381-009-0993-5; Buckon CE, Thomas SS, Piatt J, et al. Selective dorsal rhizotomy versus orthopedic surgery: a multidimensional assessment of outcome efficacy. Arch Phys Med Rehabil. 2004;85(3):457–465. doi: https://doi.org/10.1016/j.apmr.2003.05.009; Morota N. Functional posterior rhizotomy: the Tokyo experience. Childs Nerv Syst. 2007;23(9):1007–1014. doi: https://doi.org/10.1007/s00381-007-0381-y; Hurvitz EA, Marciniak CM, Daunter AK, et al. Functional outcomes of childhood dorsal rhizotomy in adults and adolescents with cerebral palsy. J Neurosurg Pediatr. 2013;11(4):380–388. doi: https://doi.org/10.3171/2013.1.PEDS12311
-
2Academic Journal
Συγγραφείς: A. L. Kurenkov, O. A. Klochkova, B. I. Bursagova, L. M. Kuzenkova, Kh. M. Karimova, A. M. Mamedyarov, A. R. Artemenko, S. A. Petrova, А. Л. Куренков, О. А. Клочкова, Б. И. Бурсагова, Л. М. Кузенкова, Х. М. Каримова, А. М. Мамедьяров, А. Р. Артеменко, С. А. Петрова
Πηγή: Neuromuscular Diseases; № 3 (2014); 28-41 ; Нервно-мышечные болезни; № 3 (2014); 28-41 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2014-0-3
Θεματικοί όροι: шкала Тардье, cerebral palsy, spasticity, spastic diplegia, hemiparesis, spastic tetraparesis, neuroorthopedics, antispasticity medications, goals of treatment, Ashworth scale, Tardieu scale, Gross motor function classification system, детский церебральный паралич, спастичность, спастическая диплегия, гемипарез, спастический тетрапарез, нейроортопедия, антиспастические препараты, цели лечения, шкала Эшворта
Περιγραφή αρχείου: application/pdf
Relation: https://nmb.abvpress.ru/jour/article/view/27/23; Koman L.A., Mooney J.F. 3rd, Smith B. et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 1993;13(4):489–95.; Graham H.K., Aoki K.R., Autti-Ramo I. et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11: 67–79.; Heinen F., Molenaers G., Fairhurst C. et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2006;10(5–6):215–25.; Heinen F., Desloovere K., Schroeder A.S. et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010;14(1):45–66.; Love S.C., Novak I., Kentish M. et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neur 2010;17(Suppl 2):9–37.; Bax M., Goldstein M., Rosenbaum P. et al. Proposed definition and classification of cerebral palsy. Dev Med Child Neurol 2005;47(8):571–6.; Miller F. Cerebral palsy. New York: Springer Science, 2005. 1055 p.; Батышева Т.Т., Быкова О.В., Виноградов А.В. Приверженность семьи к лечению ребенка с неврологической патологией. Журн неврол и психиатр им. С.С. Корсакова 2012;7(2): 56–63.; Семенова К.А., Махмудова Н.М. Медицинская реабилитация и социальная адаптация больных детским церебральным параличом. Ташкент: Медицина, 1979. 487 с.; Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000;42(12):816–24.; Palisano R., Rosenbaum P., Walter S. et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol1997;39(4):214–23.; Palisano R.J. A collaborative model of service delivery for children with movement disorders: a framework for evidence-based decision making. Phys Ther 2006;86(9): 1295–305.; Hanna S.E., Rosenbaum P.L., Bartlett D.J. et al. Stability and decline in gross motor function among children and youth with cerebral palsy aged 2 to 21 years. Dev Med Child Neurol 2009;51(4):295–302.; Eliasson A.C., Krumlinde-Sundholm L., Rösblad B. et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol 2006;48(7):549–54.; Hidecker M.J., Paneth N., Rosenbaum P.L. et al. Developing and validating the Communication Function Classification System for individuals with cerebral palsy. Dev Med Child Neurol 2011;53(8):704–10.; Hidecker M.J., Ho N.T., Dodge N. et al. Inter-relationships of functional status in cerebral palsy: analyzing gross motor function, manual ability, and communication function classification systems in children. Dev Med Child Neurol 2012;54(8):737–42.; Bohannon R.W., Smith M.B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67(2): 206–7.; Boyd R.N., Graham H.K. Objective measurement of clinical findings in the use of Botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 1999;6(Suppl. 4):23–35.; Gage J.R., Stout J.L. Gait analysis: kinematics, kinetics, electromyography, oxygen consumption and pedobarography. In: The identification and treatment of gait problems in cerebral palsy (Eds. Gage J.R., Schwartz M.H., Koop S.E., Novacheck T.F.). London: Mac Keith Press, 2009. P. 260–284.; Leonard J., Graham H.K. Treatment of motor disorders in cerebral palsy with bo tulinum neurotoxin. In book: Botulinum toxin: Therapeutic clinical practice and science (Ed. by J. Jankovic). Philadelphia: Saunders Elsevier, 2009. P. 172–191.; Simpson D.M., Gracies J.M., Graham H.K. et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70(19):1691–8.; Delgado M.R., Hirtz D., Aisen M. et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010;74(4):336–43.; Hoare B.J., Wallen M.A., Imms C. et al. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev 2010; (1):CD003469.; Sakzewski L., Ziviani J., Boyd R. Systematic review and meta-analysis of therapeutic management of upper-limb dysfunction in children with congenital hemiplegia. Pediatrics 2009;123(6):1111–22.; Артеменко А.Р., Куренков А.Л. Ботулинический токсин: вчера, сегодня, завтра. Нервно-мышечные болезни 2013;2:6–18.; Dressler D. Clinical applications of botulinum toxin. Curr Opin Microbiol 2012;15(3):325–36.; Burgen A., Dickens F., Zatman L.J. The action of botulinum toxin on the neuromusculat junction. J Phisiol 1949;109:10–24.; Grissom J.R. Chemical denervation. In book: Electrodiagnostic medicine, 2nd edition (Eds. D. Dumitru, M.J. Zwarts, A.A. Amato). Philadelphia: Hanley & Belfus, Inc., 2002. P. 479–512.; Куренков А.Л., Артеменко А.Р., Никитин С.С., Орлова О.Р. Современные представления о механизмах действия ботулинического токсина типа А. Врач 2009;7:8–12.; Giladi N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 1997;152: 132–5.; Dressler D., Saberi F.A., Barbosa E.R. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005;63:180–5.; Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43 (Suppl. 1): 9–15.; Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26 (5):785–93.; Durham P.L., Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache 2011;51 (10):1573–7.; Gazerani P., Pedersen N.S., Staahl C. et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009;141(1–2):60–9.; Dolly J.O., O’Connell M.A. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr Opin Pharmacol 2012;12:100–8.; Sutherland D.H., Kaufman K.R., Wyatt M.P. et al. Double-blind study of botulinum toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait and Posture 1999;10:1–9.; Koman L.A., Mooney J.F. 3rd, Smith B.P. et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000;20(1):108–15.; Love S.C., Valentine J.P., Blair E.M. et al. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial. Eur J Neurol 2001;8 (Suppl 5): 50–8.; Corry I.S., Cosgrove A.P., Duffy C.M. et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 1998;18(3): 304–11.; Kirschner J., Berweck S., Mall V. et al. Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option. J Neurol 2001;248(Suppl 1):28–30.; Koman L.A., Paterson Smith B., Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs 2003;5(1):11–23.; Naumann M., Albanese A., Heinen F. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006;13 (Suppl 4):35–40.; Howell K., Selber P., Graham H.K., Reddihough D. Botulinum neurotoxin A: an unusual systemic effect. J Paediatr Child Health 2007;43(6):499–501.; Crowner B.E., Brunstrom J.E., Racette B.A. Iatrogenic botulism due to therapeutic botulinum toxin a injection in a pediatric patient. Clin Neuropharmacol 2007;30(5):310–3.; Sätilä H.K., Pietikäinen T., Lehtonen-Räty P. et al. Treatment of spastic equinus gait with botulinum toxin A: Does dose matter? Analysis of a clinical cohort. Neuropediatrics 2006;37(6):344–9.; Willis A.W., Crowner B., Brunstrom J.E. et al. High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol 2007;49(11):818–22.; Molenaers G., Schörkhuber V., Fagard K. et al. Long-term use of botulinum toxin type A in children with cerebral palsy: treatment consistency. Eur J Paediatr Neurol 2009;13(5): 421–9.; Инструкция по применению лекарственного препарата для лекарственного применения Ботокс 100 ЕД. Регистрационный номер: П №011936/01, 2013.; https://nmb.abvpress.ru/jour/article/view/27
-
3Academic Journal
Συγγραφείς: Курбатов, Ю., Немкова, С., Заваденко, Н., Аргунова, Г., Снегирев, А., Говорун, С.
Θεματικοί όροι: КОМПЬЮТЕРНАЯ СТАБИЛОГРАФИЯ, ВЕРТИКАЛЬНАЯ УСТОЙЧИВОСТЬ, ДЕТСКИЙ ЦЕРЕБРАЛЬНЫЙ ПАРАЛИЧ, СПАСТИЧЕСКАЯ ДИПЛЕГИЯ, ЧЕРЕПНО-МОЗГОВАЯ ТРАВМА, СПАСТИЧЕСКИЙ ТЕТРАПАРЕЗ
Περιγραφή αρχείου: text/html
-
4Academic Journal
Πηγή: Современные проблемы науки и образования.
Περιγραφή αρχείου: text/html
